-35%

est. 2Y upside i

HealthcareSeries B

Rank

#322

Sector

Life Sciences AI / Biotech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Causaly offers a strong upside opportunity, driven by its impressive 200% YoY revenue growth and a robust competitive moat from its proprietary Bio Graph and advanced agentic AI.

Last updated: March 10, 2026

Bull (35%)+300%

Causaly's agentic AI platform achieves widespread adoption, expanding its market penetration beyond top pharmaceutical companies and leading to a strategic acquisition by a major tech or pharma player. Revenue reaches ~$150M by early 2028, justifying a $3.6B valuation at ~24x revenue multiple.

Base (30%)+155%

Causaly maintains strong growth, but competitive pressures from incumbents and other well-funded startups temper valuation multiples. The company continues to grow revenue to ~$150M by early 2028, leading to a $2.3B valuation at ~15x revenue multiple.

Bear (35%)-63%

Dominant incumbents like Microsoft or large pharmaceutical companies successfully launch competing AI platforms, eroding Causaly's market share and pricing power. Growth stalls, leading to revenue of ~$67.5M by early 2028 and a down round to a $337.5M valuation, significantly impacting common stock value.

Est. time to liquidity~2.5 years

Preference Stack Risk

moderate

Investors hold $93M in liquidation preferences, meaning common stock holders would only see returns after this amount is paid out in an exit. At the estimated current $900M valuation, this represents 10.33% of the company's value.

Dilution Risk

high

As a Series B company, Causaly will likely need at least one more significant funding round (Series C or D) before an IPO or acquisition, which will cause further dilution to existing equity holders.

Secondary Liquidity

none

There is no publicly known active secondary market for Causaly's shares at this stage, meaning liquidity for employee equity is limited until a major exit event.

Strategic Sales — 2 roles

Business Operations — 1 role

Product — 1 role

View all 7 open roles at Causaly →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Causaly's data — designed to show you've done your homework.

  • 1

    “Given the strong push by major tech companies like Microsoft into agentic AI for R&D, how is Causaly planning to maintain its competitive edge and defend its market position over the next 2-3 years?”

  • 2

    “With $45M in current revenue and 200% YoY growth, what are the key strategic priorities for scaling the business, particularly in terms of expanding beyond the top pharmaceutical companies and into new market segments within the $52.9B TAM?”

  • 3

    “As a Series B company with $93M raised, what is the anticipated timeline for a liquidity event (IPO or acquisition), and how does the company plan to manage employee equity and potential dilution in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -35% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.